JP2014506132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506132A5 JP2014506132A5 JP2013548585A JP2013548585A JP2014506132A5 JP 2014506132 A5 JP2014506132 A5 JP 2014506132A5 JP 2013548585 A JP2013548585 A JP 2013548585A JP 2013548585 A JP2013548585 A JP 2013548585A JP 2014506132 A5 JP2014506132 A5 JP 2014506132A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residue
- seq
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000539 amino acid group Chemical group 0.000 claims 164
- 239000000427 antigen Substances 0.000 claims 54
- 102000036639 antigens Human genes 0.000 claims 54
- 108091007433 antigens Proteins 0.000 claims 54
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 36
- 238000000034 method Methods 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001627 detrimental effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161460780P | 2011-01-07 | 2011-01-07 | |
| US61/460,780 | 2011-01-07 | ||
| PCT/US2012/020529 WO2012094623A2 (en) | 2011-01-07 | 2012-01-06 | Anti-il-12/il-23 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014506132A JP2014506132A (ja) | 2014-03-13 |
| JP2014506132A5 true JP2014506132A5 (enExample) | 2015-02-26 |
Family
ID=46457988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548585A Pending JP2014506132A (ja) | 2011-01-07 | 2012-01-06 | 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120288494A1 (enExample) |
| EP (1) | EP2661448A4 (enExample) |
| JP (1) | JP2014506132A (enExample) |
| KR (1) | KR20140038369A (enExample) |
| CN (1) | CN103596978A (enExample) |
| AU (1) | AU2012204237A1 (enExample) |
| BR (1) | BR112013017417A2 (enExample) |
| CA (1) | CA2821926A1 (enExample) |
| MX (1) | MX2013007904A (enExample) |
| RU (1) | RU2013136908A (enExample) |
| SG (1) | SG191874A1 (enExample) |
| TW (1) | TW201242976A (enExample) |
| WO (1) | WO2012094623A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
| AU2008205512B2 (en) * | 2007-01-16 | 2014-06-12 | Abbvie Inc. | Methods for treating psoriasis |
| KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| WO2014143540A1 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN105749252B (zh) * | 2016-04-29 | 2025-11-14 | 南方医科大学 | Il-9作为治疗血小板缺少症的药物的应用 |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112232A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
| WO2019246271A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| MX2022001305A (es) * | 2019-07-30 | 2022-05-06 | Akeso Biopharma Inc | Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo. |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| CN117659188A (zh) * | 2022-09-07 | 2024-03-08 | 南京融捷康生物科技有限公司 | 一种il-12的单域抗体及其用途 |
| CA3270918A1 (en) * | 2022-10-17 | 2024-04-25 | Rani Therapeutics, Llc | Dosage Forms and Methods of Ustekinumab |
| US20240270836A1 (en) | 2023-01-13 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2025255560A1 (en) * | 2024-06-07 | 2025-12-11 | Rush University Medical Center | Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| EP1137766B1 (en) * | 1998-12-09 | 2005-09-28 | Protein Design Labs, Inc. | Use of il-12 antibodies to treat psoriasis |
| US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| WO2004101750A2 (en) * | 2003-05-09 | 2004-11-25 | Centocor, Inc. | IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| NZ583153A (en) * | 2004-12-21 | 2011-06-30 | Centocor Ortho Biotech Inc | Anti-IL-12 antibodies, epitopes, compositions, methods and uses |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2009114040A2 (en) * | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
-
2012
- 2012-01-06 EP EP12732270.9A patent/EP2661448A4/en not_active Withdrawn
- 2012-01-06 JP JP2013548585A patent/JP2014506132A/ja active Pending
- 2012-01-06 AU AU2012204237A patent/AU2012204237A1/en not_active Abandoned
- 2012-01-06 BR BR112013017417A patent/BR112013017417A2/pt not_active IP Right Cessation
- 2012-01-06 CN CN201280004816.0A patent/CN103596978A/zh active Pending
- 2012-01-06 KR KR1020137020934A patent/KR20140038369A/ko not_active Withdrawn
- 2012-01-06 CA CA2821926A patent/CA2821926A1/en not_active Abandoned
- 2012-01-06 TW TW101100711A patent/TW201242976A/zh unknown
- 2012-01-06 US US13/374,693 patent/US20120288494A1/en not_active Abandoned
- 2012-01-06 SG SG2013052261A patent/SG191874A1/en unknown
- 2012-01-06 RU RU2013136908/10A patent/RU2013136908A/ru not_active Application Discontinuation
- 2012-01-06 MX MX2013007904A patent/MX2013007904A/es not_active Application Discontinuation
- 2012-01-06 WO PCT/US2012/020529 patent/WO2012094623A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506132A5 (enExample) | ||
| RU2013136908A (ru) | Антитела kil-12/il-23 и их применение | |
| CN106279409B (zh) | 一种寨卡病毒人源单克隆抗体及其应用 | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP2018510622A5 (enExample) | ||
| JP2013504301A5 (enExample) | ||
| JP2016020389A5 (enExample) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2013518055A5 (enExample) | ||
| JP2016501839A5 (enExample) | ||
| JP2017070289A5 (enExample) | ||
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2017527272A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2014508748A5 (enExample) | ||
| JP2018198596A5 (enExample) | ||
| JP2012526542A5 (enExample) | ||
| JP2019511911A5 (enExample) | ||
| JP2013539369A5 (enExample) | ||
| JP2018538356A5 (enExample) | ||
| JP2015518829A5 (enExample) | ||
| Meng et al. | Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein |